Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016

Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016
Published Aug 10, 2016
48 pages — Published Aug 10, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016, provides in depth analysis on Mycobacterium tuberculosis Protein Ag85A targeted pipeline therapeutics.

The report provides comprehensive information on the Mycobacterium tuberculosis Protein Ag85A, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Mycobacterium tuberculosis Protein Ag85A targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Mycobacterium tuberculosis Protein Ag85A
- The report reviews Mycobacterium tuberculosis Protein Ag85A targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mycobacterium tuberculosis Protein Ag85A targeted therapeutics and enlists all their major and minor projects
- The report assesses Mycobacterium tuberculosis Protein Ag85A targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Mycobacterium tuberculosis Protein Ag85A targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Mycobacterium tuberculosis Protein Ag85A
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strateg

  
Source:
Document ID
GMDHC0450TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Mycobacterium tuberculosis Protein Ag85A Overview61
Therapeutics Development73
  Mycobacterium tuberculosis Protein Ag85A Products under Development by Stage of Development71
  Mycobacterium tuberculosis Protein Ag85A Products under Development by Therapy Area81
  Mycobacterium tuberculosis Protein Ag85A Products under Development by Indication91
Mycobacterium tuberculosis Protein Ag85A Pipeline Products Glance101
  Early Stage Products101
Mycobacterium tuberculosis Protein Ag85A Products under Development by Companies112
Mycobacterium tuberculosis Protein Ag85A Products under Development by Universities/Institutes132
Mycobacterium tuberculosis Protein Ag85A Therapeutics Assessment155
  Assessment by Monotherapy/Combination Products151
  Assessment by Route of Administration162
  Assessment by Molecule Type182
Mycobacterium tuberculosis Protein Ag85A Companies Involved in Therapeutics Development201
  Imaxio SA201
Mycobacterium tuberculosis Protein Ag85A Drug Profiles2114
  HG-85A Drug Profile211
  HG-85A/B Drug Profile221
  HG856-A Drug Profile231
  HG856-BCG Drug Profile241
  HG856-SeV Drug Profile251
  IMX-313-TB Drug Profile261
  MVA-85A Drug Profile274
  TB/FLU-04L Drug Profile311
  tuberculosis vaccine Drug Profile321
  tuberculosis vaccine Drug Profile331
  tuberculosis vaccine 2 Drug Profile341
Mycobacterium tuberculosis Protein Ag85A Dormant Projects351
Mycobacterium tuberculosis Protein Ag85A Discontinued Products361
Mycobacterium tuberculosis Protein Ag85A Featured News &Press Releases3710
  Mar 24, 2015: World-first TB vaccination trials enter next stage371
  Oct 02, 2013: New tuberculosis vaccine will help fight 'serious public health threat'381
  Sep 03, 2013: Imaxio announces the first human clinical trial using its pro-immunogenic technology IMX313, in tuberculosis391
  Feb 04, 2013: Emergent BioSolutions Reports Publication Of Data From Phase IIb Clinical Trial For Tuberculosis Vaccine Candidate MVA85A In Lancet392
  Dec 10, 2012: University Of Cape Town Begins New study On TB Vaccine For Newborns Of HIV-positive Mothers411
  Mar 22, 2012: Emergent BioSolutions Receives NIAID Grant To Support Tuberculosis Vaccine Candidate411
  Aug 11, 2011: Aeras And Oxford-Emergent Tuberculosis Consortium Announce Start Of Phase IIb Trial Of New Investigational Tuberculosis Vaccine In Senegal And South Africa421
  Apr 28, 2011: Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant In Phase IIb Clinical Trial431
  Feb 25, 2011: Delegates From European Parliament Express Support For Rapid Development Of Emergent's New TB Vaccine441
  Apr 22, 2009: New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial in South Africa441
  Jun 23, 2008: Emergent BioSolutions And University of Oxford Form Joint Venture To Develop Advanced Tuberculosis Vaccine451
  Oct 25, 2004: TB Vaccine MVA85A Succeeds In Safety Trials461
Appendix472
  Methodology471
  Coverage471
  Secondary Research471
  Primary Research471
  Expert Panel Validation471
  Contact Us471
  Disclaimer481

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Mycobacterium-tuberculosis-Protein-Ag85A-Pipeline-Review-H2-2016-2088-16372>
  
APA:
Global Markets Direct - Market Research. (2016). Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Mycobacterium-tuberculosis-Protein-Ag85A-Pipeline-Review-H2-2016-2088-16372>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.